Local Tumor Response to Conventional Transarterial Chemoembolization following Seven-day Lenvatinib Administration Authors: Ken Kageyama, Sawako Uchida-Kobayashi, Hiroji Shinkawa, Akira Yamamoto, Naoshi Odagiri, Masahiko Kinoshita, Mariko Nakano-Maebayashi, Kazuo Asano, Hideki Fujii, Masaru Enomoto, Takeaki Ishizawa, Yukio Miki Published: 2026 ABSTRACT Purpose: To retrospectively evaluate local tumor control and imaging findings after seven-day administration of lenvatinib followed by conventional transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.Material and Methods: In this retrospective observational study, patients received lenvatinib for seven days, followed by a two-day withdrawal period, before undergoing conventional transarterial chemoembolization in routine clinical practice. The treatment efficacy of lenvatinib administration and the combination therapy was evaluated by computed tomography during hepatic arteriography and by ethiodized oil deposition on non-contrast-enhanced computed tomography after transarterial chemoembolization, respectively. Local recurrence-free survival and progression-free survival were evaluated using the Kaplan-Meier method and the modified Response Evaluation Criteria in Solid Tumors. Prognostic factors and adverse events were assessed.Results: Thirty-two patients initiated scheduled lenvatinib-transarterial chemoembolization; 25 patients with 73 nodules completed the protocol and were analyzed. Of these nodules, 56 (76.7%) showed hyperenhancement, and 17 (23.3%) showed hypoenhancement on computed tomography during hepatic arteriography. Ethiodized oil deposition with a safety margin of ≥1 mm was achieved in 60 nodules (82.2%). Local recurrence-free survival rates were 100% at three months, 91.7% at six months, and 75.9% at 12 months. Median progression-free survival was 8.0 months. Grade 3 adverse events occurred in 3 of 32 patients.Conclusions: Scheduled lenvatinib-transarterial chemoembolization demonstrated favorable local tumor control and acceptable safety in patients with unresectable hepatocellular carcinoma; however, these exploratory findings should be interpreted with caution given the single-arm retrospective design. Introduction Transarterial chemoembolization (TACE) is widely accepted as the standard treatment for intermediate-stage HCC, but its therapeutic effect is limited by high recurrence rates [1-6]. Achieving a complete response (CR) after initial TACE is associated with improved overall survival [7, 8], yet intermediate-stage HCC encompasses a heterogeneous patient population with varying tumor burden and liver function [3-5, 9-13]. In fact, most clinical guidelines consider TACE a palliative rather than curative option [4], underscoring the need for improved strategies to enhance its efficacy. Lenvatinib (LEN), an oral multikinase inhibitor targeting vascular endothelial growth factor (VEGF) and other pathways, is approved for advanced HCC and has demonstrated clinical benefits in that setting [1]. Furthermore, LEN is currently considered a second-line systemic option when immune checkpoint inhibitor-based regimens are unsuitable [14-16], and attempts to combine LEN with immunotherapy have not yet shown survival benefits [17]. Combining LEN with TACE has been explored as a means to improve outcomes in intermediate-stage HCC. The phase II TACTICS-L trial provided encouraging evidence supporting the efficacy and favorable safety profile of LEN followed by TACE in patients who were ineligible for locoregional therapy [18]. Additional studies have also demonstrated favorable outcomes with LEN combined with locoregional therapies, including TACE and hepatic arterial infusion chemotherapy [19-23]. However, these studies primarily evaluated overall prognosis, and few have focused specifically on local tumor control [24]. Short-term LEN administration prior to TACE is hypothesized to normalize tumor vasculature, enhancing intra-arterial drug delivery and mitigating the post-TACE hypoxia-induced surge in VEGF [25, 26]. Preclinical and clinical data indicate that a brief four- to seven-day course of LEN can decrease tumor perfusion and vascularity [27, 28]. It remains unclear, however, whether such short-term LEN pre-treatment translates into improved local tumor control. When performing TACE, viable tumor tissue is typically identified by hyper-enhancement on CT during hepatic arteriography (CTHA) [29]. Short-term LEN administration often results in hypovascular imaging appearances, which may create uncertainty regarding the indication for TACE due to the low expectation of ethiodized oil deposition [30]. The effect of short-term LEN on CTHA enhancement patterns and their relationship to treatment outcomes has not been fully characterized. The findings of CTHA and ethiodized oil deposition on non-contrast-enhanced CT may provide real-world evidence that supports decision-making for adding TACE after LEN. Therefore, the aim of this retrospective observational single-arm study was to evaluate local tumor control following a seven-day course of LEN administration prior to conventional TACE (the scheduled LEN-TACE approach) in patients with unresectable HCC as part of routine clinical practice. Material and Methods Subjects Patients who were treated at our center between March 2023 and September 2024 and who met the following criteria were included in the study. (1) A diagnosis of HCC that fulfilled the criteria of the Japan Society of Hepatology Guidelines [31]; (2) Barcelona Clinic Liver Cancer stage A or B [3]; (3) Child-Pugh class A, without extrahepatic metastases and without gastrointestinal varices requiring treatment; (4) received LEN for seven days; (5) undergoing conventional TACE using ethiodized oil; (6) treatment of every lesion by TACE; (7) no additional local curative therapy, such as ablation, surgical resection, or radiation therapy, within one year after TACE; (8) no subsequent systemic therapy other than LEN in patients treated with scheduled LEN-TACE; (9) contrast-enhanced CT or MRI performed following TACE; and (10) followed-up for a minimum period of six months after scheduled LEN-TACE. The exclusion criteria were (1) inability to perform TACE due to the patient's systemic condition after LEN administration, and (2) incomplete TACE for all target and non-target lesions because TACE was performed in two separate sessions. According to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria, up to five tumors (>1 cm) in the liver per enrolled patient were identified as target lesions and included in this study [32]. Our Institutional Review Board approved the study and waived the requirement for patient consent due to its retrospective nature (approval No. 2021-625). Study design and administration of LEN LEN treatment was indicated for patients whose liver function was Child-Pugh class A, and LEN was administered orally at a dose based on patient weight. Patients with an initial body weight of <60 kg or ≥60 kg received 8 mg or 12 mg of LEN daily, respectively, for seven days before TACE. After administration of LEN for seven days followed by a two-day withdrawal period, conventional TACE was performed (Supplementary Figure 1). Following conventional TACE, LEN was re-administered for 28 days after confirming recovery of liver function and general condition. Dose reduction of LEN was permitted, depending on the patient's general condition and any adverse events (AEs). Discontinuation of LEN re-administration after TACE was permitted based on the patient's general condition, AEs, and patient preference. TACE procedure TACE procedures were performed using an interventional radiology CT system (Nexaris Angio-CT; Siemens Healthcare GmbH, Forchheim, Germany). Under local anesthesia, digital subtraction angiography of the celiac artery and common hepatic artery was obtained using a 4-Fr catheter with a nonionic iodinated contrast agent (iohexol, OmnipaqueⓇ 300 iodine, 300 mg I/mL; GE Healthcare Technologies, Chicago, IL, USA). CTHA was performed by placing the catheter tip in the common hepatic artery. Contrast medium diluted with saline in a 3:7 ratio was injected at a flow rate of 2 mL/s for approximately 13-14 seconds. CT acquisition for the first phase was initiated 10 seconds after the start of injection, and the second phase was acquired 40 seconds after injection. Subsequently, CTHA and CT during arterial portography images were obtained, and CT-maximum intensity projection images of the hepatic artery were created using a three-dimensional (3D) CT workstation (Synapse Vincent; Fujifilm Corporation, Tokyo, Japan) to identify tumor-feeding arteries. These arteries were then selectively catheterized using a 4-Fr catheter and a 1.7-1.9-Fr microcatheter. Conventional TACE was performed using digital subtraction angiography, CTHA, and navigation images to avoid infusion into nontarget arteries as much as possible. An emulsion of epirubicin (Epirubicin; Nippon Kayaku Co. Ltd., Tokyo, Japan) solution and ethiodized oil (LipiodolⓇ 480 injection; Guerbet, Villepinte, France) was prepared using a three-way stopcock. The ratio of epirubicin solution to ethiodized oil was 1:1 (epirubicin solution 5 mL mixed with ethiodized oil 5 mL). After injection of the emulsion into the feeding arteries, 1-mm gelatin sponge particles (GelpartⓇ; Nippon Kayaku Co. Ltd.) were injected until tumor staining disappeared. Doses of anticancer drugs and ethiodized oil were determined based on tumor size, tumor count, and liver function. The maximum doses of ethiodized oil and epirubicin in a single TACE session were 10 mL and 50 mg, respectively. Evaluation of tumor enhancement on preoperative CT or MRI and on CTHA Tumor enhancement was evaluated on the arterial phase of preoperative CT or MRI and on CTHA and was assigned to three categories: hyper-enhancement, hypo-enhancement, and non-enhancement. The CTHA images obtained in the first phase were used for the present analysis. Hyper-enhancement was defined as stronger staining than that of the surrounding normal liver parenchyma. Hypo-enhancement was defined as enhancement equal to or weaker than that of the surrounding liver parenchyma. Non-enhancement was defined as no staining in the entire lesion, suggesting complete necrosis. If any part of the nodule showed enhancement equal to or weaker than that of the surrounding parenchyma or showed no staining, it was classified as a hypo-enhancing nodule. Two board-certified radiologists (K.K. and A.Y.) assigned the three enhancement categories based on the CTHA findings. Cohen's kappa coefficient was calculated to determine interobserver agreement, and cases with discordant results were resolved by joint consensus. Macroscopic tumor type was determined on imaging according to the classification of the Liver Cancer Study Group of Japan as simple nodular, simple nodular with extranodular growth, confluent multinodular, or infiltrative [33]. Follow-up and evaluations Tumor location, number, and size were assessed by preoperative CT or MRI, or by CTHA during TACE. Tumors were classified as central or peripheral based on their location: those with any portion present within 1 cm of the main trunk or first branch of the portal vein (central tumor) were classified as central zone tumors, and those outside this zone were classified as peripheral zone tumors [2]. Patients with central tumors were assigned to the central arm, and those with only peripheral tumors were assigned to the peripheral arm. Non-contrast-enhanced CT was performed immediately after TACE to assess the safety margin of ethiodized oil. A positive safety margin was defined as a thickness of at least 1 mm of ethiodized oil accumulation surrounding the tumor [34]. Radiographic response was evaluated on contrast-enhanced CT or MRI within 1-3 months after TACE according to the mRECIST criteria [32]. Local recurrence was defined according to the mRECIST criteria. A target lesion was judged as recurrent when it no longer met the definition of CR. Patients without viable lesions after TACE underwent contrast-enhanced CT or MRI screening every three months. Tumor prognosis was assessed in terms of local recurrence-free survival (LRFS) for each tumor and was defined as the time interval from the date of the scheduled LEN-TACE to the date that local recurrence was identified by screening; that is, when the lesion was no longer in a state of CR. We separately assessed patient prognosis in terms of progression-free survival (PFS), which was defined as the time from the date of TACE to the date when local recurrence or new lesions were identified by screening, including recurrence of nontarget lesions, or the date of death from any cause according to the mRECIST criteria. For efficacy analyses of local and systemic tumor control, only patients who completed the scheduled LEN-TACE were included, because LRFS and PFS cannot be assessed in patients who did not undergo TACE. Prognostic factors of PFS and LRFS were assessed using the variables listed in Tables 1 and 2, respectively. Elevated alpha-fetoprotein was defined as a serum level of ≥100 ng/mL. Overall survival was also assessed during the follow-up period. Table 1.Baseline Characteristics of Patients (n = 25).CharacteristicOverallAge (years, mean ± SD)74.7 ± 8.9Sex (male/female)18/7Etiology (viral/non-viral)17/8Primary or recurrence1/24Treatment history of surgery (no/yes)13/12Treatment history of TACE (no/yes)8/17Treatment history of systemic therapies (none/presence)21/4Albumin, g/dL (mean ± SD)3.9 ± 0.5Bilirubin, mg/dL (mean ± SD)0.7 ± 0.3PT, % (mean ± SD)83.2 ± 18.1Encephalopathy (absent/present)25/0Ascites (absent/slight)25/0Child-Pugh score (5/6)21/4ALBI score (mean ± SD)–2.62 ± 0.45Largest tumor diameter (cm, mean ± SD)2.2 ± 1.1Tumor number (mean ± SD)3.4 ± 2.4Up-to-seven grade (in/out)18/7BCLC (A/B)13/12Tumor location (central/peripheral)11/14AFP, ng/mL (median, interquartile range)9.1, 5.2–22.6PIVKA-II, mAU/mL (median, interquartile range)80, 35–175AFP: α-fetoprotein; ALBI: albumin-bilirubin; BCLC: Barcelona Clinic Liver Cancer; PIVKA-II: protein induced by vitamin K absence or antagonists-II; PT: prothrombin time; SD: standard deviation; TACE: transarterial chemoembolization Baseline Characteristics of Patients (n = 25). AFP: α-fetoprotein; ALBI: albumin-bilirubin; BCLC: Barcelona Clinic Liver Cancer; PIVKA-II: protein induced by vitamin K absence or antagonists-II; PT: prothrombin time; SD: standard deviation; TACE: transarterial chemoembolization Table 2.Baseline Characteristics of Nodules (n = 73).CharacteristicOverallTumor diameter (cm, mean ± SD)1.6 ± 0.9Tumor diameter (n) (≤3 cm/>3 cm)66/7Newly developed/Locally recurrent70/3Co-existing tumor number (n) (≤3/>3)32/41Enhancement of nodules (hyper/hypo/none)56/17/0Tumor location (central/peripheral)19/54Safety margin of ethiodized oil (positive/negative)60/13Re-administration of lenvatinib after TACE (restart/none)39/34SD: standard deviation; TACE: transarterial chemoembolization Baseline Characteristics of Nodules (n = 73). SD: standard deviation; TACE: transarterial chemoembolization Safety assessment The safety endpoints of the study were the frequency and severity of AEs of sequential scheduled LEN-TACE. Severity was determined according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. All enrolled patients were included in the safety analysis, and AEs and complications were evaluated without exclusion. Statistical analysis Patient characteristics are summarized as the mean and standard deviation or as the median and interquartile range for continuous variables. LRFS and PFS were evaluated using the Kaplan-Meier method. The log-rank test was used to compare survival curves between tumor groups and patient groups. Fisher's exact test was used to compare categorical variables, and the Mann-Whitney U test was used to compare continuous variables. Statistical significance was determined by two-tailed tests and was considered significant at a p-value of <0.05. All analyses were performed using GraphPad Prism version 10.4.1 (GraphPad Software Inc., San Diego, CA, USA). Results Patient characteristics Thirty-two patients with HCC treated at our facility were retrospectively reviewed. Seven patients were excluded for the following reasons: failure to complete TACE due to deterioration of liver function after LEN administration (n = 1), hepatic encephalopathy after LEN administration (n = 1), incomplete treatment of all hepatic lesions because TACE was performed in two separate sessions (n = 3), anaphylactic shock during TACE (n = 1), and surgery within one year after scheduled LEN-TACE (n = 1). The remaining 25 patients who completed scheduled LEN-TACE were included in the study. In total, 73 target nodules were evaluated for local tumor response (Figure 1). Patient and tumor characteristics are summarized in Tables 1 and 2. Flow diagram of patient selection for this study. Thirty-two patients were evaluated for inclusion; seven were excluded (reasons shown in the diagram), and 25 patients underwent scheduled LEN-TACE and were analyzed. LEN: lenvatinib; TACE: transcatheter arterial chemo-embolization Scheduled LEN treatment before TACE All 32 patients completed the scheduled seven-day LEN administration. No patient required a dose reduction of LEN. Evaluation of enhancement of nodules on preoperative CT or MRI, and on CTHA Interobserver agreement for enhancement evaluation was excellent (κ = 1.0). All 73 nodules showed hyper-enhancement on preoperative contrast-enhanced CT or MRI before LEN administration. On CTHA after LEN, 56 nodules (76.7%) showed hyper-enhancement (Figure 2), and 17 nodules (23.3%) showed hypo-enhancement (Figures 3-5), with no nodules demonstrating complete non-enhancement (Figure 6). Among the hypo-enhancing nodules, 14 showed peripheral ring-shaped enhancement, and three showed weak enhancement throughout the lesion. All nodules were classified as the simple nodular type. Representative case of hyper-enhancement on CTHA with full deposition of ethiodized oil on CT post-TACE. a) Arterial phase of contrast-enhanced CT before LEN administration shows an enhancing HCC nodule. b) CT during arterial portography shows a perfusion defect in the nodule. c) CTHA image shows hyper-enhancement of the entire nodule. d) Ethiodized oil deposition is seen throughout the entire nodule and around the nodule just after TACE on non-enhanced CT. e) Ethiodized oil deposition is confirmed on non-enhanced CT one month after TACE. f) Ethiodized oil deposition remains apparent on non-enhanced CT one year after TACE. White arrows indicate the HCC nodule. CTHA: CT during hepatic arteriography; LEN: lenvatinib; TACE: transarterial chemoembolization Representative case of hypo-enhancement with ring-shaped strong staining and weak or no staining centrally on CTHA, and full deposition of ethiodized oil on CT post-TACE. a) Arterial phase of contrast-enhanced CT before LEN administration shows an enhancing HCC nodule. b) CT during arterial portography shows a perfusion defect in the nodule. c) CTHA image shows hypo-enhancement with ring-shaped strong staining and weak or no staining within the entire nodule. d) Ethiodized oil deposition is seen throughout the nodule and around the nodule just after TACE on non-enhanced CT. e) Ethiodized oil deposition is confirmed on non-enhanced CT one month after TACE. f) Ethiodized oil deposition remains apparent on non-enhanced CT one year after TACE. White arrows indicate HCC nodules. CTHA: CT during hepatic arteriography; LEN: lenvatinib; TACE: transarterial chemoembolization Representative case of hypo-enhancement with ring-shaped strong staining and weak or no staining centrally on CTHA and ring-shaped ethiodized oil deposition on CT post-TACE. a) Arterial phase of contrast-enhanced CT before LEN administration shows an enhancing HCC nodule. b) CT during arterial portography shows a perfusion defect in the nodule. c) CTHA image shows hypo-enhancement with ring-shaped strong staining and weak or no staining within the entire nodule. d) Ring-shaped ethiodized oil deposition is seen in the nodule just after TACE on non-enhanced CT. e) Ethiodized oil deposition is confirmed on non-enhanced CT one month after TACE. f) Ethiodized oil deposition remains apparent on non-enhanced CT one year after TACE. White arrows indicate HCC nodules. CTHA: CT during hepatic arteriography; LEN: lenvatinib; TACE: transarterial chemoembolization Representative case of hypo-enhancement with weak staining on CTHA and full deposition of ethiodized oil on CT post-TACE. a) Arterial phase of contrast-enhanced CT before LEN administration shows an enhancing HCC nodule. b) CT during arterial portography shows a perfusion defect in the nodule. c) CTHA image shows hypo-enhancement with weak staining in the nodule. d) Full deposition of ethiodized oil is seen in the nodule just after TACE on non-enhanced CT. e) Ethiodized oil deposition is confirmed on non-enhanced CT one month after TACE. f) Ethiodized oil deposition remains apparent on non-enhanced CT one year after TACE. White arrows indicate HCC nodules. CTHA: CT during hepatic arteriography; LEN: lenvatinib; TACE: transarterial chemoembolization Schematic representation of CTHA enhancement patterns and ethiodized oil deposition after TACE following seven-day lenvatinib administration, and the status of enhancement on CTHA and ethiodized oil deposition after TACE for 73 nodules in this study. CTHA: CT during hepatic arteriography; NA: not applicable; TACE: transarterial chemoembolization Ethiodized oil deposition in nodules Complete intratumoral ethiodized oil deposition was achieved in 69 of 73 nodules (94.5%), regardless of CTHA enhancement pattern (Figures 2, 3, and 5). Among the 17 hypo-enhancing nodules, 13 showed complete intratumoral deposition (Figures 3 and 5), whereas the remaining four demonstrated rim-shaped deposition (Figure 4). A positive safety margin (≥1 mm) was obtained in 60 nodules (82.2%). Local tumor response The LRFS rates of all 73 nodules were 100% at three months, 91.7% at six months, and 75.9% at one year (Figure 7a). These rates were 100%, 95.8%, and 83.0%, respectively, in peripheral tumors and 100%, 77.9%, and 51.8%, respectively, in central tumors at the same time points (Figure 7b). LRFS rates were 100%, 94.6%, and 80.0%, respectively, for tumors with a positive safety margin; and 100%, 76.8%, and 57.2%, respectively, for tumors without a positive safety margin at these time points (Figure 7c). The median LRFS of all nodules was not reached (95% CI: not available [NA]; Figure 7a); that of peripheral tumors was not reached (95% CI: NA; Figure 7b); that of central tumors was not reached (95% CI: NA; Figure 7b); that of tumors with a positive safety margin was not reached (95% CI: NA; Figure 7c); and that of tumors without a positive safety margin was 13.4 months (95% CI: 13.0-19.0; Figure 7c). LRFS was significantly longer in peripheral tumors than in central tumors and in tumors with a positive safety margin than in those without a positive safety margin (p = 0.034 and p = 0.004, respectively). No significant differences in LRFS were observed according to CTHA enhancement pattern or post-TACE LEN re-administration (Figure 7d and e). Kaplan-Meier curves of LRFS after short-term LEN administration followed by TACE. a) All tumors: Median LRFS not reached (95% CI: not available). b) Peripheral tumor vs. central tumor: Median LRFS not reached (95% CI: not available) vs. not reached (95% CI: not available); p = 0.034. c) Positive safety margin vs. no positive safety margin: Median LRFS not reached (95% CI: not available) vs. 13.4 months (95% CI: 13.0-19.0); p = 0.004. d) Hyper-enhancement vs. hypo-enhancement: Median LRFS not reached (95% CI: not available) vs. not reached (95% CI: not available); p = 0.878. e) Re-administration of LEN vs. no re-administration: Median LRFS not reached (95% CI: not available) vs. not reached (95% CI: not available); p = 0.401. *p < 0.05. LEN: lenvatinib; LRFS: local recurrence-free survival; TACE: transarterial chemoembolization PFS and overall survival Among all 25 patients, PFS rates were 100% at three months, 60.0% at six months, and 30.2% at one year (Figure 8a). Among baseline characteristics (Table 1), only alfa-fetoprotein was significantly associated with PFS, which was shorter in patients with high alfa-fetoprotein levels (p < 0.001; Figure 8b). Median PFS was 8.0 months for all patients (95% CI: 6.0-8.5), 7.9 months for patients with low alfa-fetoprotein levels (95% CI: 5.6-10.8), and 4.2 months for patients with high alfa-fetoprotein levels (95% CI: 3.1-8.2). No significant difference in PFS was observed between patients who resumed LEN after TACE and those who did not. Median overall survival was not reached (95% CI: NA; Supplementary Figure 2). Two patients died during follow-up due to disease progression after scheduled LEN-TACE. Kaplan-Meier curves of PFS after short-term LEN administration followed by TACE. a) All patients: Median PFS was 8.0 months (95% CI: 6.0-8.5). b) Low alfa-fetoprotein vs. high alfa-fetoprotein: median PFS 7.9 months (95% CI: 5.6-10.8) vs. 4.2 months (95% CI: 3.1-8.2); p = 0.005. *p<0.05. LEN: lenvatinib; PFS: progression-free survival; TACE: transarterial chemoembolization AEs After LEN administration, one patient developed hepatic encephalopathy, and one patient experienced deterioration of liver function; both events were grade 3 according to the CTCAE, and these patients did not undergo TACE. One patient experienced anaphylaxis during TACE and did not complete the procedure. Three patients developed biloma after TACE (grade 1 according to the CTCAE), all of which resolved spontaneously without additional treatment. One patient developed portal vein thrombosis (grade 3 according to the CTCAE) after TACE, which resolved after one month of oral anticoagulant therapy. Overall, three of the 32 patients experienced grade 3 AEs. There were no treatment-related deaths. Discussion This study evaluated local tumor response following seven-day LEN administration and subsequent scheduled LEN-TACE. On CTHA, 76.7% of nodules showed hyper-enhancement and 23.3% showed hypo-enhancement, whereas no nodules demonstrated complete non-enhancement, indicating preserved tumor viability at the time of TACE. Importantly, no significant differences in local tumor control were observed between enhancement patterns. Nearly all nodules showed ethiodized oil deposition on post-TACE CT, regardless of CTHA findings, supporting the role of TACE after short-term LEN administration. Short-term LEN administration has been shown to reduce tumor perfusion and vascularity in both preclinical and clinical studies [27, 28, 35]. In the present cohort, all nodules were hyper-enhancing before LEN administration, whereas approximately 20% showed hypo-enhancement on CTHA after LEN. However, most nodules retained partial enhancement, and no nodules demonstrated complete non-enhancement, indicating preserved tumor viability at the time of TACE. Pharmacokinetic data indicate that plasma concentrations of LEN decline within 24 hours after cessation of administration [36]. Therefore, after a two-day withdrawal period, the perfusion-suppressing effect of LEN is likely to be attenuated. Taken together, a seven-day LEN regimen followed by a two-day withdrawal may induce a transient reduction in intratumoral perfusion, followed by partial recovery of tumor perfusion by the time of TACE, underscoring the importance of timely embolization. In this study, both hyper- and hypo-enhancing nodules showed substantial ethiodized oil deposition after TACE. Complete intratumoral deposition was achieved in most nodules, including those with hypo-enhancement on CTHA, suggesting that reduced enhancement does not preclude effective embolization. These findings support ethiodized oil deposition as a radiographic surrogate of tumor response [37, 38]. Effective deposition may reflect a combination of LEN-related vascular changes and meticulous ultraselective TACE techniques, although the relative contribution of each factor could not be determined in this single-arm study [39, 40]. This study found LRFS rates of 100% at three months, 91.7% at six months, and 75.9% at one year. Peripheral tumors exhibited significantly better LRFS than central tumors, and tumors with a positive safety margin showed superior outcomes. Compared with previous data, these results are encouraging. A large-cohort study reported LRFS rates after TACE monotherapy for treatment-naïve HCC of 78.4% at three months, 67.6% at six months, and 54.8% at one year [2]. In the present cohort, peripheral tumors achieved LRFS rates of 95.8% and 83.0% at six and 12 months, respectively, compared with 76.1% and 62.9% in the previous study. For central tumors, the corresponding rates were 77.9% and 51.8% in the present cohort versus 35.2% and 23.2% in the historical cohort [2]. These findings suggest improved local control with LEN-TACE, particularly for central tumors, which are traditionally more challenging to treat. Although differences in patient background and study design limit direct comparisons, these results should be interpreted as exploratory. Consistent with this concept, the TACTICS-L trial reported improved PFS and CR rates with sequential LEN-TACE compared with TACE alone [41]. Tumor location and safety margin remained significant prognostic factors for local control (Figure 7a and b), whereas post-TACE LEN re-administration had no significant impact. These findings suggest that technical aspects of TACE may play a more dominant role in local tumor control than systemic therapy in this setting. Short-term LEN administration prior to TACE was generally well tolerated, although a small number of patients experienced grade 3 AEs that precluded TACE. Tachiiri et al. [27] performed four-day LEN administration before TACE and reported three cases of grade 1 AEs in 25 patients. Given that long-term LEN administration is associated with cumulative toxicity [42], minimizing the duration of pre-TACE LEN administration may be important to ensure treatment feasibility. Further studies are needed to define the optimal duration of short-term LEN administration. Biloma occurred in a small proportion of patients after TACE and resolved spontaneously without additional treatment, consistent with previous reports on conventional TACE [43]. LEN combined with drug-eluting bead TACE (DEB-TACE) has been reported to cause bile duct dilatation or biloma in 7.6% of cases [44]. In general, biloma is considered more likely to occur after DEB-TACE than after conventional TACE [45]. It remains unclear whether LEN contributes to bile duct injury, but scheduled LEN-TACE appeared to be well tolerated in this cohort. This study has several limitations. It was a single-center retrospective study, and larger prospective studies are required to validate these findings. In addition, because this was a single-arm study of short-term LEN administration followed by TACE, it remains uncertain whether the observed outcomes are truly superior to those of TACE alone. Three patients with widely distributed tumors who underwent TACE in two separate sessions were excluded, which may have introduced selection bias. Furthermore, post-TACE LEN re-administration was not randomized; therefore, comparisons between patients who did and did not resume LEN should be interpreted with caution. The follow-up duration was relatively short (minimum six months), which may be insufficient to assess long-term outcomes. Only 25 of the 32 patients who initiated the protocol were included in the efficacy analysis because seven patients could not undergo TACE, potentially leading to an overestimation of efficacy and safety. In addition, pre-treatment imaging modalities and timing were not standardized, and the interval between baseline contrast-enhanced CT or MRI and intra-procedural CTHA varied among patients, which may have influenced the assessment of tumor size and enhancement patterns. Scheduled short-term LEN followed by TACE showed favorable local tumor control with acceptable safety; however, these exploratory findings should be interpreted with caution given the single-arm retrospective design. This approach may enhance TACE outcomes and warrants further validation. Author Contributions KK and SU-K conceived the ideas, contributed to the interpretation of data, and drafted the manuscript. KK, SU-K, and AY contributed to the interpretation of data and reviewed the manuscript critically. SU-K and AY reviewed the manuscript critically. KK and SU-K are the guarantors of this work and have full access to all the data in the study. All the authors have read and approved the final manuscript. Conflicts of Interest Author AY is a member of the Editorial Board of this journal but was not involved in the editorial decision or peer review of this manuscript. Ethics Approval and Consent to Participate This retrospective study was approved by our Institutional Committee on Human Investigation (reference number, 2021-625). Disclosure statement Author AY is a member of the Editorial Board of this journal but was not involved in the editorial decision or peer review of this manuscript. Supplementary Material Treatment flow of scheduled LEN–TACE. Seven days of lenvatinib administration are indicated by black arrows. Two days of withdrawal are indicated by gray arrows. The day of TACE is indicated by the black arrowhead. LEN: lenvatinib; TACE: transcatheter arterial chemo-embolization. Kaplan–Meier curves of OS after short-term LEN administration followed by TACE. All patients: Median OS not reached (95% CI: not available). LEN: lenvatinib; OS: overall survival; TACE: transarterial chemoembolization.